Sign Up Today and Learn More About BridGene Biosciences Stock
Invest in or calculate the value of your shares in BridGene Biosciences or other pre-IPO companies through EquityZen's platform.
BridGene Biosciences Stock (BRBI)
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules.
About BridGene Biosciences Stock
Founded
2018
Headquarters
Sunnyvale, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
BridGene Biosciences Press Mentions
Stay in the know about the latest news on BridGene Biosciences
BridGene Biosciences Raises $28 Million to Advance Small Molecule Drug Development
venturecapital • Jan 30, 2026
BridGene Biosciences Closes $28M Series B+
vcnewsdaily • Jan 29, 2026
BridGene Biosciences Appoints Nobel Laureate Bruce A. Beutler, M.D., to Scientific Advisory Board
prnewswire • Jan 05, 2026
uBriGene Launches LVV Turbo(TM) - Its Next-Generation GMP Lentiviral Vector Manufacturing Platform - and announces a Strategic Partnership with Syenex for integration of its UltraCell(TM) Technology
biospace • Dec 16, 2025
uBriGene Biosciences and Circurna Announce Strategic Partnership to Accelerate Development and Manufacturing of Circular RNA/LNP Therapeutics
newswire • Dec 10, 2025
BridGene Biosciences Management
Leadership team at BridGene Biosciences
Head of Biology
C. Glenn Begley
Co-Founder and CEO
Ping Cao
Join now and verify your accreditation status to gain access to:
- BridGene Biosciences Current Valuation
- BridGene Biosciences Stock Price
- BridGene Biosciences Management
- Available deals in BridGene Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- BridGene Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- BridGene Biosciences Revenue and Financials
- BridGene Biosciences Highlights
- BridGene Biosciences Business Model
- BridGene Biosciences Risk Factors
- BridGene Biosciences Research Report from SACRA Research
Trading BridGene Biosciences Stock
How to invest in BridGene Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like BridGene Biosciences through EquityZen funds. These investments are made available by existing BridGene Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell BridGene Biosciences stock?
Shareholders can sell their BridGene Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
